Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for activation (specific immune response), whereas the alternative pathway can be activated by C3 ...

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...